Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder - Early effects on mood, performance, and vital signs

被引:5
作者
Uhlenhuth, E. H.
Starcevic, Vladan
Qualls, Clifford
Antal, Edward J.
Matuzas, William
Javaid, Javaid I.
Barnhill, Jamie
机构
[1] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA
[2] Univ Sydney, Sydney, NSW 2006, Australia
[3] Nepean Hosp, Sydney, NSW, Australia
[4] Jasper Clin, Kalamazoo, MI USA
[5] Maine Gen Med Ctr, Waterville, ME USA
[6] Univ Illinois, Chicago, IL USA
关键词
D O I
10.1097/01.jcp.0000236653.85791.60
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to ascertain the relationship of alprazolam plasma levels and an anxiety-prone cognitive style to the characteristics and severity of early withdrawal after abrupt discontinuation of alprazolam in 26 patients with panic disorder. After 8 and 9 weeks of fixed-dose treatment, patients were hospitalized for 24 hours. On I admission, ordered at random, treatment was maintained; on the other, placebo was substituted double blind. The Anxious Thoughts and Tendencies questionnaire was administered before treatment. Alprazolam plasma levels were measured 7 times on the day after each admission. Before each blood sampling, the Profile of Mood States and performance tasks were administered, and vital signs were recorded. On the day after abrupt discontinuation of alprazolam, Profile of Mood States anxiety, depression, fatigue, and confusion increased; vigor and elation decreased; speed on the digit symbol substitution task improved; and systolic blood pressure increased substantially over time. High Anxious Thoughts and Tendencies scores were related specifically to more anxiety. Our findings (1) confirm that dysphoric mood, fatigue, low energy, confusion, and elevated systolic blood pressure are part of the early syndrome of withdrawal from alprazolam in patients with panic disorder, notably as the drop in plasma levels approaches 50%; (2) indicate a psychomotor deficit persisting beyond dose stabilization; (3) suggest that an anxiety-prone cognitive style measurable before undertaking treatment may be a risk factor for more severe anxiety upon discontinuation; and (4) provide a rationale for applying cognitive behavior therapy during benzodiazepine taper.
引用
收藏
页码:519 / 523
页数:5
相关论文
共 26 条
[1]  
BALLENGER JC, 1988, ARCH GEN PSYCHIAT, V45, P413
[2]   Cognitive-behavioral therapy, imipramine, or their combination for panic disorder - A randomized controlled trial [J].
Barlow, DH ;
Gorman, JM ;
Shear, MK ;
Woods, SW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (19) :2529-2536
[3]  
BECK A T, 1976, P356
[4]  
Beck AT., 1985, ANXIETY DISORDERS PH
[5]   Are benzodilazepines still the medication of choice for patients with panic disorder with or without agoraphobia? [J].
Bruce, SE ;
Vasile, RG ;
Goisman, RM ;
Salzman, C ;
Spencer, M ;
Machan, JT ;
Keller, MB .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (08) :1432-1438
[6]   Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: A long-term follow-up of the Peoria and Dartmouth studies [J].
Bruce, TJ ;
Spiegel, DA ;
Hegel, MT .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1999, 67 (01) :151-156
[7]   ASSESSMENT OF FEAR OF FEAR IN AGORAPHOBICS - THE BODY SENSATIONS QUESTIONNAIRE AND THE AGORAPHOBIC COGNITIONS QUESTIONNAIRE [J].
CHAMBLESS, DL ;
CAPUTO, GC ;
BRIGHT, P ;
GALLAGHER, R .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1984, 52 (06) :1090-1097
[8]  
Cohen J., 1988, STAT POWER ANAL BEHA
[9]   LENGTH OF TREATMENT WITH ANXIOLYTIC SEDATIVES AND RESPONSE TO THEIR SUDDEN WITHDRAWAL [J].
COVI, L ;
LIPMAN, RS ;
PATTISON, JH ;
DEROGATIS, LR ;
UHLENHUTH, EH .
ACTA PSYCHIATRICA SCANDINAVICA, 1973, 49 (01) :51-64
[10]   PANIC DISORDER, AGORAPHOBIA, AND ANXIETY-RELEVANT COGNITIVE-STYLE [J].
GANELLEN, RJ ;
MATUZAS, W ;
UHLENHUTH, EH ;
GLASS, R ;
EASTON, CR .
JOURNAL OF AFFECTIVE DISORDERS, 1986, 11 (03) :219-225